{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:04:11Z","timestamp":1771020251523,"version":"3.50.1"},"reference-count":148,"publisher":"Elsevier","isbn-type":[{"value":"9780128196687","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/b978-0-12-819668-7.00014-2","type":"book-chapter","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T05:14:17Z","timestamp":1599196457000},"page":"353-393","source":"Crossref","is-referenced-by-count":5,"title":["Nanotechnological approaches in cancer"],"prefix":"10.1016","author":[{"given":"Jo\u00e3o","family":"Basso","sequence":"first","affiliation":[]},{"given":"Maria","family":"Mendes","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Vitorino","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Pais","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Vitorino","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/B978-0-12-819668-7.00014-2_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.bbcan.2019.04.005","article-title":"Drug repurposing in oncology: compounds, pathways, phenotypes and computational approaches for colorectal cancer","volume":"1871","author":"Nowak-Sliwinska","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.drudis.2018.11.022","article-title":"The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions","volume":"24","author":"Polamreddy","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib4","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s10620-014-3040-7","article-title":"Topiramate use does not reduce flares of inflammatory bowel disease","volume":"59","author":"Crockett","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib5","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3389\/fphar.2017.00478","article-title":"Hurdles in basic science translation","volume":"8","author":"Perry","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib6","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bph.13895","article-title":"Drug repurposing screens and synergistic drug-combinations for infectious diseases","volume":"175","author":"Zheng","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib8","first-page":"173","article-title":"Repurposing drugs for glioblastoma: from bench to bedside","volume":"428","author":"Basso","year":"2018","journal-title":"Cancer Lett 10.1016\/j.canlet.2018.04.039"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib9","article-title":"Drug repositioning and repurposing: terminology and definitions in literature","volume":"20","author":"Langedijk","year":"2015","journal-title":"Drug Discov Today 10.1016\/j.drudis.2015.05.001"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.neuropharm.2018.08.027","article-title":"CNS repurposing-Potential new uses for old drugs: examples of screens for Alzheimer's disease, Parkinson's disease and spasticity","volume":"147","author":"Parsons","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib11","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2174\/1389200218666170607101622","article-title":"Repurposed drugs as potential therapeutic candidates for the management of Alzheimer's disease","volume":"18","author":"Shoaib","year":"2017","journal-title":"Curr Drug Metabol"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib12","series-title":"ClinicalTrials.gov","year":"2019"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib13","doi-asserted-by":"crossref","first-page":"172784","DOI":"10.1016\/j.ejphar.2019.172784","article-title":"Old wine in new bottles: drug repurposing in oncology","volume":"866","author":"Antoszczak","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib14","doi-asserted-by":"crossref","first-page":"e114633","DOI":"10.1371\/journal.pone.0114633","article-title":"Non-steroidal anti-inflammatory drugs use is associated with reduced risk of inflammation-associated cancers: NIH-AARP study","volume":"9","author":"Shebl","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib15","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/1940-6207.CAPR-16-0209","article-title":"Targeting inflammation in cancer prevention and therapy","volume":"9","author":"Todoric","year":"2016","journal-title":"Cancer Prev Res"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib16","article-title":"Role of nonsteroidal anti-inflammatory drugs (NSAIDs) in cancer prevention and cancer promotion","volume":"2019","author":"Wong","year":"2019","journal-title":"Adv Pharmacol Sci"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3390\/pharmaceutics10040181","article-title":"Targeted theranostic nanoparticles for brain tumor treatment","volume":"10","author":"Mendes","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2174\/1381612043453144","article-title":"Cyclooxygenase enzymes: regulation and function","volume":"10","author":"Fitzpatrick","year":"2004","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1357-2725(98)00152-6","article-title":"Cyclooxygenase-1 and-2 isoenzymes","volume":"31","author":"Hla","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S1388-1981(99)00147-X","article-title":"The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins","volume":"1441","author":"Garavito","year":"1999","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib21","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1046\/j.1365-2044.2000.01271.x","article-title":"Cyclo-oxygenase isoenzymes: physiological and pharmacological role","volume":"55","author":"Kam","year":"2000","journal-title":"Anaesthesia"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib22","series-title":"Prostanoids in health and disease","first-page":"423","author":"Smyth","year":"2009"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00001813-200202000-00003","article-title":"COX-2 inhibitors in cancer treatment and prevention, a recent development","volume":"13","author":"Xu","year":"2002","journal-title":"Anticancer Drugs 10.1097\/00001813-200202000-00003"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib24","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.2147\/JPR.S186000","article-title":"Safety of celecoxib versus traditional nonsteroidal anti-inflammatory drugs in older patients with arthritis","volume":"11","author":"Shin","year":"2018","journal-title":"J Pain Res"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib25","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib26","unstructured":"PubChem. Characteristics of clecoxib. n.d."},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40362-015-0034-6","article-title":"Celecoxib for the right person at the right dose and right time: an updated overview","volume":"3","author":"Domiati","year":"2015","journal-title":"Springer Sci Rev"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib28","unstructured":"Celecoxib pathway, pharmacodynamics overview | PharmGKB. n.d."},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib29","year":"2020","journal-title":"DrugBank. Celecoxib"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003088-200038030-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of celecoxib","volume":"38","author":"Davies","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib31","year":"2018","journal-title":"PubChem Celecoxib"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib32","first-page":"4375","article-title":"Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations","volume":"61","author":"Shono","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejps.2018.08.019","article-title":"Biotinylated PAMAM G3 dendrimer conjugated with celecoxib and\/or Fmoc-l-Leucine and its cytotoxicity for normal and cancer human cell lines","volume":"124","author":"Uram","year":"2018","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib34","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ijpharm.2014.07.028","article-title":"New celecoxib multiparticulate systems to improve glioblastoma treatment","volume":"473","author":"Vera","year":"2014","journal-title":"Int J Pharm"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11060-017-2380-5","article-title":"Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt\/survivin-and Akt\/ID3 pathway in low-grade-glioma","volume":"132","author":"Sato","year":"2017","journal-title":"J Neuro Oncol"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib36","first-page":"1","article-title":"Cyclooxygenase-2 induction by amino acid deprivation requires p38 mitogen-activated protein kinase in human glioma cells","volume":"0","author":"Li","year":"2017","journal-title":"Cancer Invest 10.1080\/07357907.2017.1292517"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib37","first-page":"1073","article-title":"Prostaglandin E 2 plays a major role in glioma resistance and progression","volume":"5","author":"Oliver","year":"2016","journal-title":"Transl Cancer Res 10.21037\/tcr.2016.11.20"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/FPC.0b013e32834f94cb","article-title":"Celecoxib pathways: pharmacokinetics and pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib39","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1517\/17460441.2014.883377","article-title":"The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies","volume":"9","author":"Vosooghi","year":"2014","journal-title":"Expet Opin Drug Discov"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejphar.2015.11.007","article-title":"Cyclooxygenase-2 inhibitors in lung cancer treatment: bench to bed","volume":"769","author":"Liu","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib41","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.2147\/CMAR.S175212","article-title":"Advances in antitumor effects of NSAIDs","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib42","article-title":"Celecoxib enhances the sensitivity of non-small-cell lung cancer cells to radiation-induced apoptosis through downregulation of the Akt\/mTOR signaling pathway and COX-2 expression","volume":"14","author":"Zhang","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib43","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1038\/s41598-017-06673-3","article-title":"Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma","volume":"7","author":"Chiang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib44","article-title":"Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt\/survivin- and Akt\/ID3 pathway in low-grade-glioma","volume":"0","author":"Sato","year":"2017","journal-title":"J Neuro Oncol 10.1007\/s11060-017-2380-5"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib45","series-title":"ClinicalTrials.gov","year":"2020"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib46","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1166\/jbn.2019.2730","article-title":"A facile strategy to generate high drug payload celecoxib micelles for enhanced corneal permeability","volume":"15","author":"Bao","year":"2019","journal-title":"J Biomed Nanotechnol"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejpb.2019.02.008","article-title":"Silk fibroin nanoparticles for celecoxib and curcumin delivery: ROS-scavenging and anti-inflammatory activities in an in vitro model of osteoarthritis","volume":"137","author":"Crivelli","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib48","doi-asserted-by":"crossref","first-page":"115209","DOI":"10.1016\/j.carbpol.2019.115209","article-title":"Development of celecoxib eye drop solution and microsuspension: a comparative investigation of binary and ternary cyclodextrin complexes","volume":"225","author":"Jansook","year":"2019","journal-title":"Carbohydr Polym"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib49","first-page":"1131","article-title":"Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma","volume":"11","author":"Ju","year":"2016","journal-title":"Int J Nanomed"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib50","doi-asserted-by":"crossref","first-page":"7610","DOI":"10.1016\/j.biomaterials.2014.05.040","article-title":"Liposomes, modified with PTDHIV-1 peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer","volume":"35","author":"Ju","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib51","doi-asserted-by":"crossref","first-page":"100288","DOI":"10.1016\/j.nanoso.2019.100288","article-title":"Synthesis and characterization of celecoxib loaded PEGylated liposome nanoparticles for biomedical applications","volume":"18","author":"Dave","year":"2019","journal-title":"Nano-Struct Nano-Objects"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2019.01.002","article-title":"Nanoliposomal formulation encapsulating celecoxib and genistein inhibiting COX-2 pathway and Glut-1 receptors to prevent prostate cancer cell proliferation","volume":"448","author":"Tian","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib53","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/1535-7163.MCT-16-0285","article-title":"Nanoparticle-based celecoxib and plumbagin for the synergistic treatment of melanoma","volume":"16","author":"Gowda","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib54","article-title":"Multi-reservoir phospholipid shell encapsulating protamine nanocapsules for Co-delivery of Letrozole and Celecoxib in breast cancer therapy","author":"Elzoghby","year":"2017","journal-title":"Pharm Res 10.1007\/s11095-017-2207-2"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib55","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1021\/acs.molpharmaceut.8b01123","article-title":"Cell permeable NBD peptide-modified liposomes by hyaluronic acid coating for the synergistic targeted therapy of metastatic inflammatory breast cancer","volume":"16","author":"Sun","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib56","doi-asserted-by":"crossref","first-page":"109874","DOI":"10.1016\/j.msec.2019.109874","article-title":"Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia","author":"\u00dcner","year":"2019","journal-title":"Mater Sci Eng C"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib57","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s11095-013-0984-9","article-title":"Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel","volume":"30","author":"Patel","year":"2013","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib58","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jconrel.2010.02.006","article-title":"Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers","volume":"144","author":"Patlolla","year":"2010","journal-title":"J Contr Release"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib59","doi-asserted-by":"crossref","first-page":"10071","DOI":"10.1038\/s41598-017-09520-7","article-title":"Celecoxib normalizes the tumor microenvironment and enhances small nanotherapeutics delivery to A549 tumors in nude mice","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-019-0540-9","article-title":"pH and redox dual-responsive nanoparticles based on disulfide-containing poly (\u03b2-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer","volume":"17","author":"Zhang","year":"2019","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2016.03.025","article-title":"Nebulizable colloidal nanoparticles co-encapsulating a COX-2 inhibitor and a herbal compound for treatment of lung cancer","volume":"103","author":"Said-Elbahr","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib62","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1039\/C6NJ02819E","article-title":"Lipid\u2013polymer hybrid nanoparticles for synergistic drug delivery to overcome cancer drug resistance","volume":"41","author":"Zeng","year":"2017","journal-title":"New J Chem"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib63","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1039\/C7TB00655A","article-title":"Fusion peptide functionalized hybrid nanoparticles for synergistic drug delivery to reverse cancer drug resistance","volume":"5","author":"Wu","year":"2017","journal-title":"J Mater Chem B"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib64","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jddst.2018.02.004","article-title":"Development and in vitro evaluation of doxorubicin and celecoxib co-loaded bone targeted nanoparticles","volume":"45","author":"Kozlu","year":"2018","journal-title":"J Drug Deliv Sci Technol"},{"issue":"6","key":"10.1016\/B978-0-12-819668-7.00014-2_bib65","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1021\/acsnano.9b02149","article-title":"Core-Shell-distinct nanodrug showing on-demand sequential drug release to act on multiple cell types for synergistic anticancer therapy","volume":"13","author":"Huang","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib66","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1039\/C8BM00381E","article-title":"Regulating the Golgi apparatus by co-delivery of a COX-2 inhibitor and Brefeldin A for suppression of tumor metastasis","volume":"6","author":"Yu","year":"2018","journal-title":"Biomater Sci"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib67","doi-asserted-by":"crossref","first-page":"8555","DOI":"10.1021\/acsami.8b00875","article-title":"Celecoxib-induced self-assembly of smart albumin-doxorubicin conjugate for enhanced cancer therapy","volume":"10","author":"Shi","year":"2018","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib68","doi-asserted-by":"crossref","first-page":"1801987","DOI":"10.1002\/advs.201801987","article-title":"Redox-Responsive dual drug delivery nanosystem suppresses cancer repopulation by abrogating doxorubicin-promoted cancer stemness, metastasis, and drug resistance","volume":"6","author":"Liu","year":"2019","journal-title":"Adv Sci"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib69","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.colsurfb.2016.10.029","article-title":"Co-delivery of multiple drug resistance inhibitors by polymer\/inorganic hybrid nanoparticles to effectively reverse cancer drug resistance","volume":"149","author":"Wu","year":"2017","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib70","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.actbio.2016.10.042","article-title":"Microfluidic assembly of a nano-in-micro dual drug delivery platform composed of halloysite nanotubes and a pH-responsive polymer for colon cancer therapy","volume":"48","author":"Li","year":"2017","journal-title":"Acta Biomater"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib71","doi-asserted-by":"crossref","DOI":"10.2217\/nnm-2018-0028","article-title":"Layer-by-layer gelatin\/chondroitin quantum dots-based nanotheranostics: combined rapamycin\/celecoxib delivery and cancer imaging","volume":"13","author":"AbdElhamid","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib72","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2217\/nnm-2018-0196","article-title":"Lactoferrin-tagged quantum dots-based theranostic nanocapsules for combined COX-2 inhibitor\/herbal therapy of breast cancer","volume":"13","author":"AbdElhamid","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib73","series-title":"Chapter 23: ethanol. Goodman Gilman's pharmacol. Basis ther.","author":"Brunton","year":"2018"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib74","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.1992.tb03309.x","article-title":"The pharmacology and toxicology of disulfiram and its metabolites","volume":"86","author":"Petersen","year":"1992","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib75","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0447.1992.tb03310.x","article-title":"A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites","volume":"86","author":"Johansson","year":"1992","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib76","unstructured":"National Center for Biotechnology Information. PubChem Database. Disulfiram, CID=3117. n.d. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Disulfiram [Accessed 3 January 2020]."},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib77","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ctrv.2008.07.004","article-title":"Elevated copper and oxidative stress in cancer cells as a target for cancer treatment","volume":"35","author":"Gupte","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib78","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0009-9120(85)80078-3","article-title":"Copper, zinc and copper\/zinc ratio in chronic pancreatitis and pancreatic cancer","volume":"18","author":"Fabris","year":"1985","journal-title":"Clin Biochem"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib79","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1021\/jm8007807","article-title":"Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells","volume":"51","author":"Cvek","year":"2008","journal-title":"J Med Chem 10.1021\/jm8007807"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib80","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2174\/0929867324666171023161121","article-title":"Recent advances in Antabuse (disulfiram): the importance of its metal-binding ability to its anticancer activity","volume":"25","author":"Viola-Rhenals","year":"2018","journal-title":"Curr Med Chem"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib81","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/bjc.2011.126","article-title":"Disulfiram modulated ROS\u2013MAPK and NF\u03baB pathways and targeted breast cancer cells with cancer stem cell-like properties","volume":"104","author":"Yip","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib82","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/ijc.21534","article-title":"Inhibition of proteasome activity, nuclear factor-KB translocation and cell survival by the antialcoholism drug disulfiram","volume":"118","author":"L\u00f6vborg","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib83","doi-asserted-by":"crossref","first-page":"10425","DOI":"10.1158\/0008-5472.CAN-06-2126","article-title":"Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity","volume":"66","author":"Chen","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib84","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nature25016","article-title":"Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4","volume":"552","author":"Skrott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib85","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1002\/ange.201814519","article-title":"Universal anticancer Cu (DTC) 2 discriminates between thiols and zinc (II) thiolates oxidatively","volume":"131","author":"Xu","year":"2019","journal-title":"Angew Chem"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib86","doi-asserted-by":"crossref","first-page":"13221","DOI":"10.1073\/pnas.95.22.13221","article-title":"Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK","volume":"95","author":"Takahashi","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib87","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1023043315031","article-title":"RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling","volume":"22","author":"Noda","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib88","doi-asserted-by":"crossref","first-page":"252","DOI":"10.18632\/oncotarget.136","article-title":"A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs","volume":"1","author":"Murai","year":"2010","journal-title":"Oncotarget"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib89","doi-asserted-by":"crossref","first-page":"41118","DOI":"10.1021\/acsami.8b14940","article-title":"Disulfiram copper nanoparticles prepared with a stabilized metal ion ligand complex method for treating drug-resistant prostate cancers","volume":"10","author":"Chen","year":"2018","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib90","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/bjc.2013.534","article-title":"Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells","volume":"109","author":"Liu","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib91","first-page":"1488","article-title":"Cytotoxic effect of disulfiram\/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells","volume":"107","author":"Liu","year":"2012","journal-title":"Br J Cancer 10.1038\/bjc.2012.442"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib92","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2174\/156800911794519806","article-title":"Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome","volume":"11","author":"Cvek","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib93","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1021\/mp049917l","article-title":"Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein","volume":"1","author":"Loo","year":"2004","journal-title":"Mol Pharm"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib94","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1124\/mol.65.3.675","article-title":"The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1)","volume":"65","author":"Sauna","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib95","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/pros.21247","article-title":"Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth","volume":"71","author":"Lin","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib96","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.18632\/oncotarget.23320","article-title":"Brain-and brain tumor-penetrating disulfiram nanoparticles: sequence of cytotoxic events and efficacy in human glioma cell lines and intracranial xenografts","volume":"9","author":"Rao Madala SRP","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib97","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/carcin\/bgt366","article-title":"Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage","volume":"35","author":"Paranjpe","year":"2014","journal-title":"Carcinogenesis 10.1093\/carcin\/bgt366"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib98","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1006\/bbrc.2001.6027","article-title":"Disulfiram is a potent in vitro inhibitor of DNA topoisomerases","volume":"289","author":"Yakisich","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib99","doi-asserted-by":"crossref","first-page":"65900","DOI":"10.18632\/oncotarget.19539","article-title":"Cell cycle specific radiosensitisation by the disulfiram and copper complex","volume":"8","author":"Tesson","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib100","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ijc.1565","article-title":"Cu\/Zn superoxide dismutase plays a role in angiogenesis","volume":"97","author":"Marikovsky","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib101","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.canlet.2015.07.029","article-title":"Copper improves the anti-angiogenic activity of disulfiram through the EGFR\/Src\/VEGF pathway in gliomas","volume":"369","author":"Li","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib102","doi-asserted-by":"crossref","first-page":"18821","DOI":"10.18632\/oncotarget.24568","article-title":"Novel therapeutic features of disulfiram against hepatocellular carcinoma cells with inhibitory effects on a disintegrin and metalloproteinase 10","volume":"9","author":"Goto","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib103","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbagen.2018.09.018","article-title":"Pancreatic cancer stem cell proliferation is strongly inhibited by diethyldithiocarbamate-copper complex loaded into hyaluronic acid decorated liposomes","volume":"1863","author":"Marengo","year":"2019","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib104","doi-asserted-by":"crossref","first-page":"7471","DOI":"10.18632\/oncotarget.2166","article-title":"Liposome encapsulated Disulfiram inhibits NF\u03baB pathway and targets breast cancer stem cells in vitro and in vivo","volume":"5","author":"Liu","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib105","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.2147\/IJN.S137347","article-title":"Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent","volume":"12","author":"Wehbe","year":"2017","journal-title":"Int J Nanomed"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib106","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3390\/pharmaceutics11110610","article-title":"Development of injectable PEGylated liposome encapsulating disulfiram for colorectal cancer treatment","volume":"11","author":"Najlah","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib107","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijpharm.2018.12.051","article-title":"Integrating the drug, disulfiram into the vitamin E-TPGS-modified PEGylated nanostructured lipid carriers to synergize its repurposing for anti-cancer therapy of solid tumors","volume":"557","author":"Banerjee","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib108","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jddst.2019.03.037","article-title":"In vitro and in vivo evaluation of biotin-mediated PEGylated nanostructured lipid as carrier of disulfiram coupled with copper ion","volume":"51","author":"Liu","year":"2019","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib109","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ejlt.201400278","article-title":"Formulation and preparation of a stable intravenous disulfiram-loaded lipid emulsion","volume":"117","author":"Chen","year":"2015","journal-title":"Eur J Lipid Sci Technol"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-019-0565-0","article-title":"Soybean lecithin stabilizes disulfiram nanosuspensions with a high drug-loading content: remarkably improved antitumor efficacy","volume":"18","author":"Li","year":"2020","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib111","doi-asserted-by":"crossref","first-page":"25147","DOI":"10.1021\/acsami.5b06488","article-title":"A copper-mediated disulfiram-loaded pH-triggered PEG-shedding TAT peptide-modified lipid nanocapsules for use in tumor therapy","volume":"7","author":"Zhang","year":"2015","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib112","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1021\/nn4010796","article-title":"Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram","volume":"7","author":"Duan","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib113","doi-asserted-by":"crossref","first-page":"8631","DOI":"10.2147\/IJN.S144452","article-title":"pH-triggered surface charge-switchable polymer micelles for the co-delivery of paclitaxel\/disulfiram and overcoming multidrug resistance in cancer","volume":"12","author":"Huo","year":"2017","journal-title":"Int J Nanomed"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib114","doi-asserted-by":"crossref","first-page":"125102","DOI":"10.1088\/0957-4484\/25\/12\/125102","article-title":"Multi-targeted inhibition of tumor growth and lung metastasis by redox-sensitive shell crosslinked micelles loading disulfiram","volume":"25","author":"Duan","year":"2014","journal-title":"Nanotechnology"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib115","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1021\/acs.molpharmaceut.7b01094","article-title":"mPEG5k-b-PLGA2k\/PCL3. 4k\/MCT mixed micelles as carriers of disulfiram for improving plasma stability and antitumor effect in vivo","volume":"15","author":"Miao","year":"2018","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/B978-0-12-819668-7.00014-2_bib116","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1021\/acs.biomac.9b00367","article-title":"Highly stable, coordinated polymeric nanoparticles loading copper (II) diethyldithiocarbamate for combinational chemo\/chemodynamic therapy of cancer","volume":"20","author":"Peng","year":"2019","journal-title":"Biomacromolecules"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib117","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.actbio.2017.12.023","article-title":"Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly","volume":"68","author":"He","year":"2018","journal-title":"Acta Biomater"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib118","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.nano.2015.10.022","article-title":"Stable loading and delivery of disulfiram with mPEG-PLGA\/PCL mixed nanoparticles for tumor therapy","volume":"12","author":"Song","year":"2016","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib119","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11095-018-2414-5","article-title":"Membrane loaded copper oleate pegylated liposome combined with disulfiram for improving synergistic antitumor effect in vivo","volume":"35","author":"Zhou","year":"2018","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12951-016-0183-z","article-title":"Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: in vitro and in vivo investigations","volume":"14","author":"Fasehee","year":"2016","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib121","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.msec.2016.03.023","article-title":"The inhibitory effect of disulfiram encapsulated PLGA NPs on tumor growth: different administration routes","volume":"63","author":"Fasehee","year":"2016","journal-title":"Mater Sci Eng C"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib122","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.nano.2016.02.013","article-title":"Anti-proliferative and apoptosis-triggering potential of disulfiram and disulfiram-loaded polysorbate 80-stabilized PLGA nanoparticles on hepatocellular carcinoma Hep3B cell line","volume":"12","author":"Hoda","year":"2016","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib123","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1039\/C8BM00271A","article-title":"Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core\u2013shell\u2013corona nanoparticles","volume":"6","author":"Tao","year":"2018","journal-title":"Biomater Sci"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib124","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4155\/tde.14.99","article-title":"Influence of stabilizers on the production of disulfiram-loaded poly (lactic-co-glycolic acid) nanoparticles and their anticancer potential","volume":"6","author":"Hoda","year":"2015","journal-title":"Ther Deliv"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib125","doi-asserted-by":"crossref","first-page":"FSO263","DOI":"10.4155\/fsoa-2017-0091","article-title":"Stabilizers influence drug\u2013polymer interactions and physicochemical properties of disulfiram-loaded poly-lactide-co-glycolide nanoparticles","volume":"4","author":"Hoda","year":"2017","journal-title":"Futur Sci OA"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib126","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.nano.2016.08.001","article-title":"Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells","volume":"13","author":"Wang","year":"2017","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib127","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejpb.2016.11.032","article-title":"Development and characterisation of disulfiram-loaded PLGA nanoparticles for the treatment of non-small cell lung cancer","volume":"112","author":"Najlah","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1515\/ejnm-2017-0013","article-title":"Disulfiram and disulfiram-loaded poly-[lactide-co-glycolic acid] nanoparticles modulate metastatic markers and proteasomal activity in hepatocarcinoma Hep3b cell line","volume":"9","author":"Hoda","year":"2017","journal-title":"Eur J Nanomed"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib129","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1021\/acsmacrolett.6b00777","article-title":"Anticancer drug disulfiram for in situ RAFT polymerization: controlled polymerization, multifacet self-assembly, and efficient drug delivery","volume":"5","author":"Zhou","year":"2016","journal-title":"ACS Macro Lett"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcis.2018.05.057","article-title":"Disulfiram-loaded mixed nanoparticles with high drug-loading and plasma stability by reducing the core crystallinity for intravenous delivery","volume":"529","author":"Zhuo","year":"2018","journal-title":"J Colloid Interface Sci"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib131","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11095-018-2370-0","article-title":"A smart paclitaxel-disulfiram nanococrystals for efficient MDR reversal and enhanced apoptosis","volume":"35","author":"Mohammad","year":"2018","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib132","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijpharm.2018.12.067","article-title":"Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer","volume":"557","author":"Mohammad","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib133","doi-asserted-by":"crossref","first-page":"1700403","DOI":"10.1002\/adfm.201700403","article-title":"Dual-targeting to cancer cells and M2 macrophages via biomimetic delivery of mannosylated albumin nanoparticles for drug-resistant cancer therapy","volume":"27","author":"Zhao","year":"2017","journal-title":"Adv Funct Mater"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib134","doi-asserted-by":"crossref","first-page":"11531","DOI":"10.1021\/jacs.9b03503","article-title":"Enhanced tumor-specific disulfiram chemotherapy by in situ Cu2+ chelation-initiated nontoxicity-to-toxicity transition","volume":"141","author":"Wu","year":"2019","journal-title":"J Am Chem Soc"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib135","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1039\/C9RA09468G","article-title":"Globular protein stabilized nanoparticles for delivery of disulfiram: fabrication, characterization, in vitro toxicity, and cellular uptake","volume":"10","author":"Farooq","year":"2020","journal-title":"RSC Adv"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib136","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1248\/bpb.23.327","article-title":"Effects of lipid composition on the transcorneal penetration of liposomes containing disulfiram, a potential anti-cataract agent, in the rabbit","volume":"23","author":"Ito","year":"2000","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib137","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.colsurfb.2017.08.037","article-title":"Octa-arginine modified lipid emulsions as a potential ocular delivery system for disulfiram: a study of the corneal permeation, transcorneal mechanism and anti-cataract effect","volume":"160","author":"Liu","year":"2017","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib138","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2217\/nnm.12.5","article-title":"Minimally invasive drug delivery to the cochlea through application of nanoparticles to the round window membrane","volume":"7","author":"Buckiov\u00e1","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib139","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.exer.2015.01.022","article-title":"A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure","volume":"132","author":"Nagai","year":"2015","journal-title":"Exp Eye Res"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib140","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/02713680490513209","article-title":"Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats","volume":"29","author":"Wang","year":"2004","journal-title":"Curr Eye Res"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib141","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1211\/0022357044526","article-title":"An ocular drug delivery system containing zinc diethyldithiocarbamate and HP\u03b2CD inclusion complex-corneal permeability, anti-cataract effects and mechanism studies","volume":"56","author":"Wang","year":"2004","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib142","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1248\/bpb.30.1529","article-title":"Delay in ICR\/f rat lens opacification by the instillation of eye drops containing disulfiram and hydroxypropyl-\u03b2-cyclodextrin inclusion complex","volume":"30","author":"Nagai","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib143","first-page":"596","article-title":"Permeability and anticataract effects of a topical ocular drug delivery system of disulfiram","volume":"1","author":"Wang","year":"2008","journal-title":"Int Conf Biomed Eng Informatics"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib144","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1248\/bpb.33.1574","article-title":"Reduction in intraocular pressure by the instillation of eye drops containing disulfiram included with 2-hydroxypropyl-\u03b2-cyclodextrin in rabbit","volume":"33","author":"Ito","year":"2010","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib145","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3109\/02713683.2011.622853","article-title":"Effects of instillation of eyedrops containing disulfiram and hydroxypropyl-\u03b2-cyclodextrin inclusion complex on endotoxin-induced uveitis in rats","volume":"37","author":"Kanai","year":"2012","journal-title":"Curr Eye Res"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib146","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1248\/bpb.b16-00592","article-title":"An ophthalmic formulation of disulfiram nanoparticles prolongs drug residence time in lens","volume":"39","author":"Nagai","year":"2016","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib147","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0378-5173(85)90201-7","article-title":"Solubilization of drugs by modified \u03b2-cyclodextrins","volume":"26","author":"M\u00fcller","year":"1985","journal-title":"Int J Pharm"},{"key":"10.1016\/B978-0-12-819668-7.00014-2_bib148","first-page":"1199","article-title":"Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans","volume":"37","author":"Kristinsson","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Drug Repurposing in Cancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128196687000142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128196687000142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:09:06Z","timestamp":1771016946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128196687000142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128196687"],"references-count":148,"URL":"https:\/\/doi.org\/10.1016\/b978-0-12-819668-7.00014-2","relation":{},"subject":[],"published":{"date-parts":[[2020]]}}}